StockData
Immunome Inc. logo

Immunome Inc. (IMNM) stock

IMNMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$16.78−0.40 (-2.33%)

Close on Nov 18, 2026Market cap $1.91BP/E –Yield –

Immunome operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Immunome's operating income for the twelve months ending Mar 31, 2026 was -$238.81M. For fiscal 2025 it was -$224.11M. The highest annual figure on record is -$10.35M in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$224.11M–
FY2024Dec 31, 2024-$305.80M–
FY2023Dec 31, 2023-$109.53M–
FY2022Dec 31, 2022-$36.90M–
FY2021Dec 31, 2021-$25.20M–
FY2020Dec 31, 2020-$12.26M–
FY2019Dec 31, 2019-$10.35M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2026Mar 31, 2026-$59.33M–
Q4 FY2025Dec 31, 2025-$72.86M–
Q3 FY2025Sep 30, 2025-$60.14M–
Q2 FY2025Jun 30, 2025-$46.48M–
Q1 FY2025Mar 31, 2025-$44.64M–
Q4 FY2024Dec 31, 2024-$82.97M–
Q3 FY2024Sep 30, 2024-$50.52M–
Q2 FY2024Jun 30, 2024-$40.01M–
Q1 FY2024Mar 31, 2024-$132.30M–
Q4 FY2023Dec 31, 2023-$94.65M–
Q3 FY2023Sep 30, 2023-$4.63M–
Q2 FY2023Jun 30, 2023-$5.77M–
Q1 FY2023Mar 31, 2023-$4.47M–
Q4 FY2022Dec 31, 2022-$7.79M–
Q3 FY2022Sep 30, 2022-$8.53M–
Q2 FY2022Jun 30, 2022-$8.93M–
Q1 FY2022Mar 31, 2022-$11.65M–
Q4 FY2021Dec 31, 2021-$7.84M–
Q3 FY2021Sep 30, 2021-$7.72M–
Q2 FY2021Jun 30, 2021-$5.74M–
Q1 FY2021Mar 31, 2021-$3.90M–
Q4 FY2020Dec 31, 2020-$4.07M–
Q3 FY2020Sep 30, 2020-$2.82M–
Q2 FY2020Jun 30, 2020-$2.72M–
Q1 FY2020Mar 31, 2020-$2.66M–
Q4 FY2019Dec 31, 2019-$2.89M–
Q3 FY2019Sep 30, 2019-$2.72M–

More Immunome figures

See a number that looks wrong?